Abstract
Interferon (IFN)-alpha 2b is used for adjuvant therapy in malignant melanoma. Neurotoxicity as a side effect has been well described. Resting and action tremor related to interferon have been reported but are relatively uncommon. We report a case of a delayed-onset interferon-related action tremor in a patient with malignant melanoma.
MeSH terms
-
Aged
-
Antineoplastic Agents / adverse effects*
-
Female
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / adverse effects*
-
Melanoma / drug therapy*
-
Recombinant Proteins
-
Severity of Illness Index
-
Skin Neoplasms / drug therapy*
-
Tremor / chemically induced*
Substances
-
Antineoplastic Agents
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins